UB Paderborn / Katalog / Suche / in CDI

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

British journal of cancer, 2014-08, Vol.111 (4), p.660-666

2014

Volltextzugriff (PDF)

Activity and safety of ipatasertib (ipat) for AKT activating mutation and/ or PTEN loss/loss of function solid tumors from MyTACTIC

European journal of cancer (1990), 2022-10, Vol.174, p.S71-S71

2022

Volltextzugriff (PDF)

66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S571

2022

Volltextzugriff (PDF)

Role of sarcoplasmic reticulum in regulation of tonic contraction of rabbit basilar artery

American journal of physiology. Heart and circulatory physiology, 2001-10, Vol.281 (4), p.H1481-H1489

2001

Volltextzugriff (PDF)

A phase Ila dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

British journal of cancer, 2014, Vol.111 (4), p.660-666

2014

Volltextzugriff (PDF)

Augmented Contractile Response of Vascular Smooth Muscle in a Diabetic Mouse Model

Journal of vascular research, 2003-11, Vol.40 (6), p.520-530

2003

Volltextzugriff (PDF)

S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC)

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.S5-S5-1

2011

Volltextzugriff (PDF)

Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.S3-S3-2

2010

Volltextzugriff (PDF)

Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.5114-5114

2009

Volltextzugriff (PDF)

Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.1022-1022

2009

Volltextzugriff (PDF)

Agonist‐induced mitochondrial Ca2+ transients in smooth muscle

The FASEB journal, 2003-01, Vol.17 (1), p.28-37

2003

Volltextzugriff (PDF)

Basal calcium entry in vascular smooth muscle

European journal of pharmacology, 2004-11, Vol.505 (1), p.19-29

2004

Volltextzugriff (PDF)

Sequential opening of IP3-sensitive Ca2+ channels and SOC during alpha -adrenergic activation of rabbit vena cava

American journal of physiology. Heart and circulatory physiology, 2002-05, Vol.282 (5), p.H1768

2002

Volltextzugriff (PDF)

Sequential opening of IP sub(3)-sensitive Ca super(2+) channels and SOC during alpha -adrenergic activation of rabbit vena cava

American journal of physiology. Heart and circulatory physiology, 2002-05, Vol.282 (5), p.H1768-H1777

2002

Volltextzugriff (PDF)

Agonist-induced mitochondrial Ca super(2+) transients in smooth muscle

The FASEB journal, 2003-01, Vol.17 (1), p.28-37

2003

Volltextzugriff (PDF)

Endowment Risk Management and Return Enhancement with Listed Index and ETF Options

The Journal of investing, 2024-02, Vol.33 (2), p.136-167

Szado, Edward

2024

Volltextzugriff (PDF)

Environmental, social, and governance practices and perceived tail risk

Accounting and finance (Parkville), 2020-12, Vol.60 (4), p.4195-4224

2020

Volltextzugriff (PDF)

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2012-05, Vol.30 (14), p.1594-1600

2012

Volltextzugriff (PDF)

VIX Futures and options: A Case Study of Portfolio Diversification During the 2008 Financial Crisis

The journal of alternative investments, 2009-09, Vol.12 (2), p.68-85

Szado, Edward

2009

Volltextzugriff (PDF)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Breast cancer research : BCR, 2017-02, Vol.19 (1), p.16-16, Article 16

2017

Volltextzugriff (PDF)

Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca²⁺ release and apoptosis

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (7), p.2427-2432

2008

Volltextzugriff (PDF)

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes

The oncologist (Dayton, Ohio), 2024-06, Vol.29 (6), p.534-542

2024

Volltextzugriff (PDF)

Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6507-6507

2023

Volltextzugriff (PDF)

A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS1588-TPS1588

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Activity and safety of ipatasertib (ipat) for AKT activating mutation and/ or PTEN loss/loss of function solid tumors from MyTACTIC

66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors

Role of sarcoplasmic reticulum in regulation of tonic contraction of rabbit basilar artery

A phase Ila dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Augmented Contractile Response of Vascular Smooth Muscle in a Diabetic Mouse Model

S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC)

Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')

Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation

Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer

Agonist‐induced mitochondrial Ca2+ transients in smooth muscle

Basal calcium entry in vascular smooth muscle

Sequential opening of IP3-sensitive Ca2+ channels and SOC during alpha -adrenergic activation of rabbit vena cava

Sequential opening of IP sub(3)-sensitive Ca super(2+) channels and SOC during alpha -adrenergic activation of rabbit vena cava

Agonist-induced mitochondrial Ca super(2+) transients in smooth muscle

Endowment Risk Management and Return Enhancement with Listed Index and ETF Options

Environmental, social, and governance practices and perceived tail risk

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

VIX Futures and options: A Case Study of Portfolio Diversification During the 2008 Financial Crisis

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca²⁺ release and apoptosis

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes

Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO)

A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

Suchergebnisse filtern